TAAR1: the metabolic target after GLP-1

A review published in the Handbook of Experimental Pharmacology on 11 July 2026 makes a case that trace amine-associated receptor 1 (TAAR1) deserves serious attention as a metabolic drug target, placing it alongside semaglutide and the broader GLP-1 receptor agonist class rather than beneath it^[1]. The authors, Lenham, Elgammal, Harding and Berry, are not announcing a new approved drug. They are drawing a line between what TAAR1 does at the molecular level and where GLP-1 based medicines currently fall short.

What is TAAR1?

TAAR1 (trace amine-associated receptor 1) is a G-protein coupled receptor found in pancreatic beta-cells, the gut, and discrete appetite-regulating regions of the brain. Its natural ligands are trace amines, compounds present at very low concentrations in mammalian tissue. Raab and colleagues at Roche demonstrated in 2015 that activating TAAR1 with a selective small-molecule agonist increased glucose-dependent insulin secretion from pancreatic cells and elevated plasma GLP-1 and PYY levels in mice^[2]. That paper introduced the phrase "incretin-like" to describe TAAR1 activation, and it is the foundational mechanistic reference the 2026 review builds on.

The signal path in beta-cells runs through cAMP-dependent protein kinase A and exchange protein activated by cAMP, the same second-messenger cascade that GLP-1 receptor agonists use to potentiate insulin release. Michael, Covic and Kuliopulos characterised this pathway in human insulin-secreting cells in 2019, confirming TAAR1 activation also drives CREB phosphorylation and downstream expression of IRS-2, a gene that supports beta-cell survival and proliferation.

How TAAR1 compares to the GLP-1 pathway

Both GLP-1 receptor agonists and TAAR1 agonists increase glucose-dependent insulin secretion and reduce food intake. The mechanistic overlap is real. But the Lenham review notes a distinction: GLP-1 receptor agonists act at a receptor whose primary stimulation is peripheral (gut, pancreas), and the central appetite effect is secondary and partly mediated through vagal afferent pathways. TAAR1, by contrast, is expressed in homeostatic and hedonic feeding centres in the brain independently of peripheral GLP-1 release. Dedic and colleagues confirmed in a 2024 Molecular Metabolism study that three TAAR1 agonists including ulotaront reduced body weight, food intake, and liver triglycerides in obese animal models by acting on both peripheral and central circuits^[3].

The practical difference the review emphasises is the neurobehavioural dimension. TAAR1 sits at the intersection of metabolic control and dopaminergic reward signalling. The receptor modulates the same circuits that drive compulsive eating and food-related habit formation, sometimes labelled "food noise" in the GLP-1 literature. The 2026 authors argue this dual physiological and neurobehavioural action means TAAR1 compounds could address aspects of metabolic disease that GLP-1 receptor agonists reach indirectly, if at all.

The clinical picture as of mid-2026

Ulotaront (SEP-363856), originally developed by Sunovion as a TAAR1 agonist for schizophrenia, is the compound with the most human data in a metabolic context. A 2026 open-label study by Milanovic and colleagues in Diabetes, Obesity and Metabolism enrolled schizophrenia patients with metabolic syndrome and prediabetes and reported that ulotaront reduced oral glucose tolerance test area under the curve by 19.7 h x mg/dL and lowered a mixed meal tolerance test insulin response with statistical significance (p = 0.021)^[4]. The sample was small and the design was open-label, so this is signal-generating, not confirmatory. No TAAR1 agonist is approved for type-2 diabetes or obesity.

For context on what the approved landscape looks like, the semaglutide page covers the trial evidence behind Ozempic, Rybelsus and Wegovy, and the cardiovascular-outcome data from the SELECT trial. TAAR1 agonists are a long way from that level of evidence.

What we do not know yet

The Lenham review is honest about the gaps. Most of the mechanistic work is in rodents or cell lines. The human pharmacokinetic and safety characterisation of TAAR1 agonists in a purely metabolic population is thin. There is no Phase 2 or Phase 3 trial of a TAAR1 agonist specifically designed around glucose control or weight loss in people without a concurrent psychiatric indication. The receptor's role in human brown adipose tissue thermogenesis, mentioned in the review as a possible third metabolic lever, is speculative at this stage.

The review also notes that TAAR1 agonism may not produce the degree of gastric-emptying delay that underlies much of the GLP-1 class gastrointestinal adverse-event profile. Whether that translates to a cleaner tolerability record in humans has not been tested at scale.

Where this lands

The 2026 Handbook of Experimental Pharmacology paper is a mechanistic argument, not a clinical directive. It positions TAAR1 as the kind of target that drug development programmes are now worth building around, using GLP-1 receptor agonist biology as the comparison point rather than the ceiling. Whether any TAAR1-selective compound clears the Phase 3 bar for efficacy and safety in metabolic disease is a question for trials that have not yet been designed, let alone run.

For readers tracking where the field is heading after the first generation of GLP-1 medicines, the mechanistic case in this review is a reasonable place to understand what the next molecular target conversation looks like.